CLINICAL APPLICATIONS OF ARTERIAL SPIN LABELED PERFUSION MRI

$38,442P41FY2011RRNIH

University Of Pennsylvania, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 37905305 Paper 36695294 Paper 31502710 Paper 30680976 Paper 29763672 Paper 29751289 Paper 28824123 Paper 28767621 Paper 28239652 Paper 27544505 Paper 27460711 Paper 27370153 Paper 27347478 Paper 27222794 Paper 27140763 Paper 26901812 Paper 26350896 Paper 26303178 Paper 26207147 Paper 26120204 Paper 26015810 Paper 25996891 Paper 25844314 Paper 25762748 Paper 25311569 Paper 25263944 Paper 25236594 Paper 25187033 Paper 25099319 Paper 25063755 Paper 24967878 Paper 24834022 Paper 24614912 Paper 24443217 Paper 24439328 Paper 24416473 Paper 24338944 Paper 24244206 Paper 24179814 Paper 24143268 Paper 24029054 Paper 23852501 Paper 23770408 Paper 23745147 Paper 23708193 Paper 23685226 Paper 23664401 Paper 23653267 Paper 23400938 Paper 23392384 Paper 23359872 Paper 23304651 Paper 23243386 Paper 23142069 Paper 23138407 Paper 23106049 Paper 23028560 Paper 22879054 Paper 22879012 Paper 22879011 Paper 22789842 Paper 22624014 Paper 22535702 Paper 22502579 Paper 22431193 Paper 22426208 Paper 22302557 Paper 22281486 Paper 22270722 Paper 22259099 Paper 22259098 Paper 22246782 Paper 22230285 Paper 22213239 Paper 22135087 Paper 22129642 Paper 22128105 Paper 22094481 Paper 22034913 Paper 22018493 Paper 22009759 Paper 22006897 Paper 21911412 Paper 21908126 Patent 9372245 Patent 8686727 Patent 8554305 Patent 8526695 Patent 8148982 Patent 8076936 Patent 7705596 Patent 7072706 Patent 6915151 Patent 6836114 Patent 6397095 Patent 5903149 Patent 5572126 Patent 5402785 Patent 5243289 Patent 5153515

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The overall goal of this project is to develop and implement novel approaches for studying brain function that capitalize on the recent availability of a 7 Tesla whole body MRI system at the resource. In particular, arterial spin labeled (ASL) perfusion MRI should benefit from ultra-high field due to the dual benefits of increased sensitivity and longer T1 that together produce a theoretical 4-fold increase in ASL signal as compared to 3 Tesla. However, to realize this potential gain, TRD2 needs to develop strategies to address challenges in B0 and B1 inhomogeneity and SAR deposition. We also propose to use the increased sensitivity to BOLD contrast for real-time fMRI. Technical validation will be complemented by collaborative and service projects with applications in cerebrovascular disease, peripheral vascular disease, addictions, and brain mapping. The technology development and validation being carried out in TRD2 is driven by the need to accurately measure tissue perfusion, a critical biological parameter. Disorders of perfusion account for most of the medical morbidity mortality in the western world (MI, stroke, PVD) and perfusion is also a biomarker of regional tissue function in the brain and other organs. Accordingly, the activities of TRD2 are driven by the desire to measure a fundamental physiological function. This motivation is exemplified by 2 Driving Biomedical Projects that will benefit from TRD2 activities in ASL technology development for human CBF quantification both at 7T and at 3T, as well as from future efforts to implement ASL for animal models at 9.4T.

View original record on NIH RePORTER →